Targeted therapy for esophagogastric cancers: a review

Muhammad Khattak, Hilary Martin, Christos Karapetis

    Research output: Contribution to journalReview articlepeer-review


    The incidence of esophagogastric cancers is increasing rapidly in the Western population. Despite better understanding of the biology and intense research in the treatment of these cancers, the long-term survival remains poor both in the locally advanced and metastatic settings. The addition of combined modality strategies has resulted in modest improvement in 5-year survival rates. A number of biologic agents targeting epidermal-derived growth factor receptor, vascular endothelial derived growth factor and its receptor, and mammalian target of rapamycin (mTOR) are being currently evaluated in Phase II and III clinical trials. Some of these, like trastuzumab, cetuximab, and bevacizumab, have shown promising results. This review provides a brief overview of the recent developments in biologic agents for the treatment of esophagogastric cancers.

    Original languageEnglish
    Pages (from-to)91-102
    Number of pages12
    JournalOncoTargets and Therapy
    Issue number5
    Publication statusPublished - 2012


    • Adenocarcinoma
    • Her2-positive EGC
    • Squamous cell carcinoma
    • Trastuzumab
    • VEGF


    Dive into the research topics of 'Targeted therapy for esophagogastric cancers: a review'. Together they form a unique fingerprint.

    Cite this